Lonnie Pyne
@lonniepyne.bsky.social
Nephrologist
Assistant Professor
McMaster University
Assistant Professor
McMaster University
Hi everyone. Lonnie Pyne, nephrologist from McMaster University in Hamilton, Ontario, Canada joining for #NephJC tonight.
COI - one of the authors
COI - one of the authors
September 3, 2025 at 1:02 AM
Hi everyone. Lonnie Pyne, nephrologist from McMaster University in Hamilton, Ontario, Canada joining for #NephJC tonight.
COI - one of the authors
COI - one of the authors
Reposted by Lonnie Pyne
Following #ACHIEVE our meta-analysis of RCTs of MRAs for pts receiving dialysis in @thelancet.com. Thanks to @lonniepyne.bsky.social for leading. No signal for benefit among low-risk of bias RCTs and a good demo of why we continue to need large simple trials.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials
Mineralocorticoid receptor antagonists can prevent cardiovascular events in patients with heart failure and non-severe chronic kidney disease, but the…
www.sciencedirect.com
August 19, 2025 at 4:43 AM
Following #ACHIEVE our meta-analysis of RCTs of MRAs for pts receiving dialysis in @thelancet.com. Thanks to @lonniepyne.bsky.social for leading. No signal for benefit among low-risk of bias RCTs and a good demo of why we continue to need large simple trials.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Reposted by Lonnie Pyne
Proud to have worked with colleagues and friends around the world on #ACHIEVE. We're disappointed spiro didn't prevent CV death/heart failure hospitalizations, but we've shown it's possible to do publicly funded large RCTs of repurposed meds in ESKD. More to do!
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial
Patients undergoing maintenance dialysis for kidney failure are at substantial risk of cardiovascular morbidity and mortality. We aimed to establish i…
www.sciencedirect.com
August 15, 2025 at 2:57 AM
Proud to have worked with colleagues and friends around the world on #ACHIEVE. We're disappointed spiro didn't prevent CV death/heart failure hospitalizations, but we've shown it's possible to do publicly funded large RCTs of repurposed meds in ESKD. More to do!
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...